RT @aparna1024: https://t.co/5uAmivdrjF Parikh et al., 2021 Clin Cancer Res Guardant REVEAL 📌The 1st data of plasma ONLY #ctDNA MRD study…
RT @aparna1024: https://t.co/5uAmivdrjF Parikh et al., 2021 Clin Cancer Res Guardant REVEAL 📌The 1st data of plasma ONLY #ctDNA MRD study…
RT @PamelaKunzMD: Congrats! 👏
Congrats! 👏
RT @aparna1024: https://t.co/5uAmivdrjF Parikh et al., 2021 Clin Cancer Res Guardant REVEAL 📌The 1st data of plasma ONLY #ctDNA MRD study…
RT @aparna1024: https://t.co/5uAmivdrjF Parikh et al., 2021 Clin Cancer Res Guardant REVEAL 📌The 1st data of plasma ONLY #ctDNA MRD study…
RT @aparna1024: https://t.co/5uAmivdrjF Parikh et al., 2021 Clin Cancer Res Guardant REVEAL 📌The 1st data of plasma ONLY #ctDNA MRD study…
RT @aparna1024: https://t.co/5uAmivdrjF Parikh et al., 2021 Clin Cancer Res Guardant REVEAL 📌The 1st data of plasma ONLY #ctDNA MRD study…
RT @aparna1024: https://t.co/5uAmivdrjF Parikh et al., 2021 Clin Cancer Res Guardant REVEAL 📌The 1st data of plasma ONLY #ctDNA MRD study…
RT @aparna1024: https://t.co/5uAmivdrjF Parikh et al., 2021 Clin Cancer Res Guardant REVEAL 📌The 1st data of plasma ONLY #ctDNA MRD study…
RT @aparna1024: https://t.co/5uAmivdrjF Parikh et al., 2021 Clin Cancer Res Guardant REVEAL 📌The 1st data of plasma ONLY #ctDNA MRD study…
https://t.co/5uAmivdrjF Parikh et al., 2021 Clin Cancer Res Guardant REVEAL 📌The 1st data of plasma ONLY #ctDNA MRD study 📌Genomic + epigenomic => a signal detected Y/N 📌Stage I-IV 📌N= 84 pts plasma collected after definitive tx was completed CRCTri
RT @CCR_AACR: Another fantastic #liquidbiopsy paper by @aparna1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctD…
RT @CCR_AACR: Another fantastic #liquidbiopsy paper by @aparna1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctD…
RT @CCR_AACR: Another fantastic #liquidbiopsy paper by @aparna1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctD…
RT @CCR_AACR: Another fantastic #liquidbiopsy paper by @aparna1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctD…
RT @CCR_AACR: Another fantastic #liquidbiopsy paper by @aparna1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctD…
RT @CCR_AACR: Another fantastic #liquidbiopsy paper by @aparna1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctD…
RT @CCR_AACR: Another fantastic #liquidbiopsy paper by @aparna1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctD…
RT @CCR_AACR: Another fantastic #liquidbiopsy paper by @aparna1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctD…
RT @CCR_AACR: Another fantastic #liquidbiopsy paper by @aparna1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctD…
RT @CCR_AACR: Another fantastic #liquidbiopsy paper by @aparna1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctD…
RT @CCR_AACR: Another fantastic #liquidbiopsy paper by @aparna1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctD…
RT @CCR_AACR: Another fantastic #liquidbiopsy paper by @aparna1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctD…
Another fantastic #liquidbiopsy paper by @aparna1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctDNA detection assay for miminal residual disease detection in patients with #colorectal cancer. https://t.co/V4VIcnJ0Xm #AACR22
RT @CCR_AACR: Another fantastic #liquidbiopsy paper by @aparna 1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctD…
Another fantastic #liquidbiopsy paper by @aparna 1024 and colleagues @MGHCancerCenter describes the use of a plasma-only #ctDNA detection assay for miminal residual disease detection in patients with #colorectal cancer. https://t.co/hivSyN6Ekz #AACR22
RT @pashtoonkasi: 🆕#ctDNA #LiquidBiopsies study @ASCO #GI22 @OncoAlert. Again from our colleagues in 🇯🇵 leading the way: COSMOS💫-CRC-01👇🏾.…
RT @pashtoonkasi: 🆕#ctDNA #LiquidBiopsies study @ASCO #GI22 @OncoAlert. Again from our colleagues in 🇯🇵 leading the way: COSMOS💫-CRC-01👇🏾.…
RT @pashtoonkasi: 🆕#ctDNA #LiquidBiopsies study @ASCO #GI22 @OncoAlert. Again from our colleagues in 🇯🇵 leading the way: COSMOS💫-CRC-01👇🏾.…
RT @pashtoonkasi: 🆕#ctDNA #LiquidBiopsies study @ASCO #GI22 @OncoAlert. Again from our colleagues in 🇯🇵 leading the way: COSMOS💫-CRC-01👇🏾.…
RT @pashtoonkasi: 🆕#ctDNA #LiquidBiopsies study @ASCO #GI22 @OncoAlert. Again from our colleagues in 🇯🇵 leading the way: COSMOS💫-CRC-01👇🏾.…
RT @pashtoonkasi: 🆕#ctDNA #LiquidBiopsies study @ASCO #GI22 @OncoAlert. Again from our colleagues in 🇯🇵 leading the way: COSMOS💫-CRC-01👇🏾.…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @pashtoonkasi: 🆕#ctDNA #LiquidBiopsies study @ASCO #GI22 @OncoAlert. Again from our colleagues in 🇯🇵 leading the way: COSMOS💫-CRC-01👇🏾.…
🆕#ctDNA #LiquidBiopsies study @ASCO #GI22 @OncoAlert. Again from our colleagues in 🇯🇵 leading the way: COSMOS💫-CRC-01👇🏾. 🩸PLASMA-only #methylation/#epigenomics➕#genetics. Same as in #COBRA🐍. Initial📝@CCR_AACR Nice pre➡️post surgery%📉data➕ 6.6m recurr
Take your time to read this debate rising from two milestone articles on #CRC #MRD detection through #ctDNA: it is a high-quality educative resource. I personally support landmark analysis as the clinically ideal timepoint for MRD https://t.co/luzpaswZIp &
RT @CCR_AACR: Plasma-only ctDNA-guided MRD detection in CRC patients. https://t.co/G3eJQ2vhmu https://t.co/SIfSYAJuf7
RT @CCR_AACR: Plasma-only ctDNA-guided MRD detection in CRC patients. https://t.co/G3eJQ2vhmu https://t.co/SIfSYAJuf7
RT @CCR_AACR: Plasma-only ctDNA-guided MRD detection in CRC patients. https://t.co/G3eJQ2vhmu https://t.co/SIfSYAJuf7
RT @ChristianRolfo: @isliquidbiopsy
@isliquidbiopsy
RT @CCR_AACR: Plasma-only ctDNA-guided MRD detection in CRC patients. https://t.co/G3eJQ2vhmu https://t.co/SIfSYAJuf7
RT @CCR_AACR: Plasma-only ctDNA-guided MRD detection in CRC patients. https://t.co/G3eJQ2vhmu https://t.co/SIfSYAJuf7
RT @CCR_AACR: Plasma-only ctDNA-guided MRD detection in CRC patients. https://t.co/G3eJQ2vhmu https://t.co/SIfSYAJuf7
Plasma-only ctDNA-guided MRD detection in CRC patients. https://t.co/G3eJQ2vhmu https://t.co/SIfSYAJuf7
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer https://t.co/eFrp0Fdzz2
RT @DDNewsOnline: #GuardantReveal #ctDNA #LiquidBiopsy offered 100% PPV of #CRC #recurrence following curative intent therapy Integrating…
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer https://t.co/VmanG6PEPX
RT @Al3ssandroRusso: Minimal Residual Disease Detection using a Plasma-Only ctDNA Assay in CRC Patients using the Guardant Reveal assay @is…
RT @Esanzgarcia: We knew that Tumor bespoken ctDNA was useful for MRD in CRC. Now we have some evidence with non-informed ctDNA. Intercepti…
RT @JBrosnanCashman: @lillian_siu and @mdmanishshah suggest that MRD detection in solid tumors is paradigm shifting. Work from Ryan Corcora…
@lillian_siu and @mdmanishshah suggest that MRD detection in solid tumors is paradigm shifting. Work from Ryan Corcoran (@MGHCancerCenter) supports the clinical utility of plasma ctDNA MRD detection in patients with #colorectalcancer. @CCR_AACR #AACR21 ht
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients https://t.co/7hcSIFNN3A
RT @NatRevClinOncol: In a analysis of prospective serial plasma specimens from 103 pts with CRC undergoing surgery, detectable ctDNA ~1 mon…
RT @NatRevClinOncol: In a analysis of prospective serial plasma specimens from 103 pts with CRC undergoing surgery, detectable ctDNA ~1 mon…
RT @NatRevClinOncol: In a analysis of prospective serial plasma specimens from 103 pts with CRC undergoing surgery, detectable ctDNA ~1 mon…
We knew that Tumor bespoken ctDNA was useful for MRD in CRC. Now we have some evidence with non-informed ctDNA. Interception trials needed to make more useful detection of MRD in our patients!
RT @NatRevClinOncol: In a analysis of prospective serial plasma specimens from 103 pts with CRC undergoing surgery, detectable ctDNA ~1 mon…
RT @NatRevClinOncol: In a analysis of prospective serial plasma specimens from 103 pts with CRC undergoing surgery, detectable ctDNA ~1 mon…
In a analysis of prospective serial plasma specimens from 103 pts with CRC undergoing surgery, detectable ctDNA ~1 month after surgery predicted recurrence with a sensitivity and specificity of 55.6% and 100%, respectively: https://t.co/0QawxUUzgB #CRCSM #
Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients https://t.co/4SykMDLxdR
RT @Al3ssandroRusso: Minimal Residual Disease Detection using a Plasma-Only ctDNA Assay in CRC Patients using the Guardant Reveal assay @is…
RT @Al3ssandroRusso: Minimal Residual Disease Detection using a Plasma-Only ctDNA Assay in CRC Patients using the Guardant Reveal assay @is…
RT @Al3ssandroRusso: Minimal Residual Disease Detection using a Plasma-Only ctDNA Assay in CRC Patients using the Guardant Reveal assay @is…
RT @Al3ssandroRusso: Minimal Residual Disease Detection using a Plasma-Only ctDNA Assay in CRC Patients using the Guardant Reveal assay @is…
Minimal Residual Disease Detection using a Plasma-Only ctDNA Assay in CRC Patients using the Guardant Reveal assay @isliquidbiopsy @ChristianRolfo @UmbertoMalapel1 @ddemiguelperez https://t.co/KOd7CICZJF
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @ctSEQ_papers: PubMed_ Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients…
RT @HKennecke: Impressed by this study and excited by the ⬆️ sensitivity of this @GuardantHealth ctDNA assay integrating epigenomic signatu…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
@aparna1024 & Ryan Corcoran @MGHCancerCenter has a very nice paper our on tumour-uninformed MRD using @GuardantHealth REVEAL (aka LUNAR-1)... https://t.co/ytdBMNcsjg
RT @ctSEQ_papers: PubMed_ Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients…
Guardant Health test detects residual #cancerDNA in the blood without relying on tumor data https://t.co/NN6byZKcj5 #colorectalcancer #cancer #CancerResearch #ctDNA #diagnostics #liquidbiopsy #liquidbiopsies #MRD
PubMed_ Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients https://t.co/QiOfNnCTl6
RT @k_sedge: Congrats to @aparna1024 @TedHong9 @KlempnerSam & MGH team on the CCR pub showing Guardant Reveal plasma-only MRD assay for #CR…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @HKennecke: Impressed by this study and excited by the ⬆️ sensitivity of this @GuardantHealth ctDNA assay integrating epigenomic signatu…
Impressed by this study and excited by the ⬆️ sensitivity of this @GuardantHealth ctDNA assay integrating epigenomic signatures with genomic alterations. May further improve ctDNA 💪. Nice work @aparna1024 et al #colorectalcancer #finishcancer @CCR_AACR ht
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients https://t.co/ORq5momabu
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @k_sedge: Congrats to @aparna1024 @TedHong9 @KlempnerSam & MGH team on the CCR pub showing Guardant Reveal plasma-only MRD assay for #CR…
Congrats to @aparna1024 @TedHong9 @KlempnerSam & MGH team on the CCR pub showing Guardant Reveal plasma-only MRD assay for #CRC has comp sensitivity & specificity to tumor-informed assays. No tissue need & fast TAT has great potential to help m
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
RT @aparna1024: Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. C…
Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. Can’t compare apples to apples with this limited data set but important nonetheless and sets the stage for future work https://t.co/sb